Investor Relations

Investor Relations

BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS).  BrainsWay’s flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. 

BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US.  The company also has approval in Canada, Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications.

BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders.

BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY.

See the latest SEC Filing HERE.

Latest releases
November 25, 2019
BrainsWay Reports Third Quarter 2019 Financial Results and Operational Highlights
Third quarter revenues were $5.9 million, up 38% over the same quarter in the prior year JERUSALEM, Israel and HACKENSACK, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain

Questions for the Investor Relations Department can be submitted through the form below.

Fields marked with an * are required.

For more information please contact BrainsWay at:

  • ETel: +1-844-386-7001
  • Tel: +972-2-647-6010
  • Email:

Data Provided by Refinitiv. Minimum 15 minutes delayed.